Xilio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	43.77	6.34	-	-	-
Revenue Growth (YoY)	589.88%	-	-	-	-
Gross Profit	43.77	6.34	-	-	-
Selling, General & Admin	29.71	24.78	27	29.95	23.86
Research & Development	56.04	41.21	52.14	59.2	51.19
Other Operating Expenses	-	0.94	-	-	-
Total Operating Expenses	85.75	66.93	79.13	89.15	75.04
Operating Income	-41.98	-60.58	-79.13	-89.15	-75.04
Total Non-Operating Income (Expense)	6.95	2.34	2.73	0.93	-0.76
Pretax Income	-35.04	-58.24	-76.4	-88.22	-75.8
Net Income	-35.04	-58.24	-76.4	-88.22	-75.8
Net Income to Common	-35.04	-58.24	-76.4	-88.22	-75.8
Shares Outstanding (Basic)	8	4	2	2	0
Shares Outstanding (Diluted)	8	4	2	2	0
Shares Change (YoY)	118.70%	94.61%	0.38%	388.59%	970.34%
EPS (Basic)	-4.19	-15.24	-38.92	-45.08	-189.28
EPS (Diluted)	-4.19	-15.24	-38.92	-45.08	-189.28
Shares Outstanding	4.53	3.27	1.97	1.96	1.95
Free Cash Flow	-5.51	-18.41	-69.11	-77.59	-81.85
Free Cash Flow Per Share	-0.66	-4.82	-35.19	-39.66	-204.40
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-95.92%	-954.95%	-	-	-
Profit Margin	-80.05%	-918.05%	-	-	-
FCF Margin	-12.59%	-290.26%	-	-	-
EBITDA	-40.44	-58.94	-77.23	-87.3	-73.55
EBITDA Margin	-92.40%	-929.03%	-	-	-
EBIT	-41.98	-60.58	-79.13	-89.15	-75.04
EBIT Margin	-95.92%	-954.95%	-	-	-

Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q